Add to Favourites
To login click here
Oncotelic Therapeutics, Inc. has announced the beta launch of a proprietary SEC chatbot, utilizing their DAO token (PDAO) and Artificial Intelligence (AI). This chatbot allows users to receive conversational responses about the Company’s SEC filings filed as of April 12, 2023. Only holders of the Pet2DAO token, PDAO, can access the chatbot. The chatbot can be accessed at http://chat.pet2dao.com/ and feedback can be sent to token@pet2dao.com. Pet2DAO is a DAO technology company that integrates traditional corporate governance with innovative DAO architecture using AI and Blockchain technologies.